
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549

FORM 10-Q

Quarterly Report Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

For the Quarterly Period Ended March 31, 2013

Commission File Number **0-13839**

CAS MEDICAL SYSTEMS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of
incorporation or organization)

06-1123096

(I.R.S. employer
identification no.)

44 East Industrial Road, Branford, Connecticut 06405

(Address of principal executive offices, including zip code)

(203) 488-6056

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of "large accelerated filer", "accelerated filer", and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large Accelerated Filer Accelerated Filer Non-Accelerated Filer Smaller Reporting Company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date: Common Stock, \$.004 par value 13,697,955 shares as of May 10, 2013.

INDEX

	<u>Page No.</u>
<u>PART I</u>	
<u>Financial Information</u>	
Item 1 Financial Statements (Unaudited)	3
Condensed Consolidated Balance Sheets as of March 31, 2013, and December 31, 2012	3
Condensed Consolidated Statements of Operations for the Three Months Ended March 31, 2013 and 2012	5
Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2013 and 2012	6
Notes to Condensed Consolidated Financial Statements	7
Item 2 Management's Discussion and Analysis of Financial Condition and Results of Operations	14
Item 3 Quantitative and Qualitative Disclosures about Market Risk	17
Item 4 Controls and Procedures	17
<u>PART II</u>	
<u>Other Information</u>	
Item 1 Legal Proceedings	18
Item 6 Exhibits	18
Signatures	19

PART I – FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

CAS Medical Systems, Inc.

Condensed Consolidated Balance Sheets
(Unaudited)

<u>Assets</u>	<u>March 31,</u> <u>2013</u>	<u>December 31,</u> <u>2012</u>
Current assets:		
Cash and cash equivalents	\$ 6,987,579	\$ 9,245,094
Short-term investments	757,971	1,250,794
Accounts receivable, net of allowance	2,547,660	2,197,513
Inventories	3,890,049	3,543,325
Other current assets	378,543	612,082
Total current assets	<u>14,561,802</u>	<u>16,848,808</u>
Property and equipment:		
Leasehold improvements	311,320	311,320
Equipment at customers	3,476,096	3,407,836
Machinery and equipment	<u>5,555,157</u>	<u>5,439,521</u>
	9,342,573	9,158,677
Accumulated depreciation and amortization	<u>(6,672,662)</u>	<u>(6,443,303)</u>
Property and equipment, net	<u>2,669,911</u>	<u>2,715,374</u>
Intangible and other assets, net	<u>807,549</u>	<u>830,245</u>
Total assets	<u>\$ 18,039,262</u>	<u>\$ 20,394,427</u>

CAS Medical Systems, Inc.

Condensed Consolidated Balance Sheets
(Unaudited)

<u>Liabilities and Stockholders' Equity</u>	<u>March 31,</u> <u>2013</u>	<u>December 31,</u> <u>2012</u>
Current liabilities:		
Accounts payable	\$ 1,230,718	\$ 1,906,327
Accrued expenses	1,288,829	1,625,923
Current portion of long-term debt	—	697,834
Total current liabilities	<u>2,519,547</u>	<u>4,230,084</u>
Deferred gain on sale and leaseback of property	596,493	630,152
Long-term debt less current portion	<u>3,400,871</u>	<u>2,685,560</u>
Total liabilities	<u>6,516,911</u>	<u>7,545,796</u>
Commitments and contingencies		
Stockholders' equity:		
Preferred stock, \$.001 par value per share, 1,000,000 shares authorized -		
Series A convertible preferred stock, 95,500 shares issued and outstanding, liquidation value of \$10,829,244 at March 31, 2013	8,802,000	8,802,000
Series A exchangeable preferred stock, 54,500 shares issued and outstanding; liquidation value of \$6,218,339 at March 31, 2013	5,135,640	5,135,640
Common stock, \$.004 par value per share, 40,000,000 shares authorized, 13,783,955 and 13,767,192 shares issued at March 31, 2013, and December 31, 2012, respectively, including shares held in treasury	55,136	55,069
Common stock held in treasury, at cost – 86,000 shares	(101,480)	(101,480)
Additional paid-in capital	12,284,557	12,023,721
Accumulated deficit	<u>(14,653,502)</u>	<u>(13,066,319)</u>
Total stockholders' equity	<u>11,522,351</u>	<u>12,848,631</u>
Total liabilities and stockholders' equity	<u>\$ 18,039,262</u>	<u>\$ 20,394,427</u>

See accompanying notes.

CAS Medical Systems, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended	
	March 31,	
	<u>2013</u>	<u>2012</u>
Net sales	\$ 5,575,838	\$ 5,408,819
Cost of sales	<u>3,350,856</u>	<u>3,373,745</u>
Gross profit	2,224,982	2,035,074
Operating expenses:		
Research and development	1,052,860	890,117
Selling, general and administrative	<u>3,081,754</u>	<u>3,107,521</u>
	<u>4,134,614</u>	<u>3,997,638</u>
Operating loss	(1,909,632)	(1,962,564)
Interest expense	65,729	148
Other income	<u>(388,178)</u>	<u>(16,620)</u>
Net loss	(1,587,183)	(1,946,092)
Preferred stock dividend accretion	<u>293,201</u>	<u>273,545</u>
Net loss applicable to common stockholders	<u>\$ (1,880,384)</u>	<u>\$ (2,219,637)</u>
Per share basic and diluted loss applicable to common stockholders:	<u>\$ (0.14)</u>	<u>\$ (0.17)</u>
Weighted average number of common shares outstanding:		
Basic and diluted	13,391,752	13,218,840

See accompanying notes.

CAS Medical Systems, Inc.

Condensed Consolidated Statements of Cash Flows
(Unaudited)

	Three Months Ended	
	March 31,	
	2013	2012
OPERATING ACTIVITIES:		
Net loss	\$ (1,587,183)	\$ (1,946,092)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	285,835	242,124
Amortization of debt discount	17,477	—
Stock compensation	228,419	228,648
Gain from demutualization of insurance provider	(381,058)	—
Impaired capitalized patent costs	—	27,262
Amortization of gain on sale and leaseback of property	(33,659)	(33,659)
Deferred income taxes	—	—
Changes in operating assets and liabilities:		
Accounts receivable	(350,147)	(357,558)
Inventories	(346,724)	(77,674)
Other current assets	233,539	2,797
Accounts payable and accrued expenses	(1,012,703)	115,680
Net cash used in operating activities	<u>(2,946,204)</u>	<u>(1,798,472)</u>
INVESTING ACTIVITIES:		
Expenditures for property and equipment	(213,252)	(393,840)
Short-term investments	492,823	(3,976)
Gain from demutualization of insurance provider	381,058	—
Purchase of intangible assets	(4,424)	(17,244)
Net cash provided by (used in) investing activities	<u>656,205</u>	<u>(415,060)</u>
FINANCING ACTIVITIES:		
Proceeds from issuance of common stock	32,484	10,741
Net cash provided by financing activities	<u>32,484</u>	<u>10,741</u>
Net change in cash and cash equivalents	(2,257,515)	(2,202,791)
Cash and cash equivalents, beginning of period	9,245,094	11,387,300
CASH AND CASH EQUIVALENTS, END OF PERIOD	<u><u>\$ 6,987,579</u></u>	<u><u>\$ 9,184,509</u></u>
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:		
Cash paid during the period for interest	\$ 48,253	\$ 148

See accompanying notes.

CAS Medical Systems, Inc.

**Notes to Condensed Consolidated Financial Statements
(Unaudited)**

March 31, 2013

(1) The Company

CAS Medical Systems, Inc. (the “Company” or “CASMED”) is a medical technology company that develops, manufactures, and distributes non-invasive patient monitoring products that are vital to patient care. Our products include the FORE-SIGHT® Absolute Tissue Oximeter and sensors and our Traditional Monitoring products which include MAXNIBP® blood pressure measurement technology, bedside monitoring products, and supplies for neonatal intensive care. These products are designed to provide accurate, non-invasive, biologic measurements that guide healthcare providers to deliver improved patient care. CASMED markets its products worldwide through its sales force, distributors, manufacturers’ representatives, and original equipment manufacturers.

(2) Basis of Presentation

The condensed consolidated financial statements included herein have been prepared, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and disclosures included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s Annual Report filed on Form 10-K for the year ended December 31, 2012. The condensed consolidated balance sheet as of December 31, 2012, was derived from the audited financial statements.

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales and expenses during the reporting period. Estimates that are particularly sensitive to change in the near-term are inventory valuation allowances, deferred income tax asset valuation allowances, and allowances for doubtful accounts. Actual results could differ from those estimates. In the opinion of the Company, all adjustments (consisting of normal recurring accruals) necessary to present fairly the consolidated financial position of the Company and its consolidated results of operations and cash flows have been included in the accompanying financial statements. The results of operations for interim periods are not necessarily indicative of the expected results for the full year.

(3) Preferred Stock

On June 9, 2011, the Company issued (i) 95,500 shares of “Series A Convertible Preferred Stock,” par value \$0.001 per share, which are convertible into authorized but unissued shares of common stock, par value \$0.004 per share, of the Company and (ii) 54,500 shares of “Series A Exchangeable Preferred Stock,” par value \$0.001 per share, which are convertible into authorized but unissued shares of common stock, par value \$0.004 per share, of the Company. The Series A Exchangeable Preferred Stock has substantially identical terms to the Series A Convertible Preferred Stock.

Series A Convertible Preferred Stock

The shares of Series A Convertible Preferred Stock (the “Series A Preferred Stock”) are convertible at the option of the holder into common stock at a conversion price of \$2.82 (the “Conversion Price”). The Conversion Price is subject to standard weighted-average anti-dilution adjustments.

Following the date of issuance, the stated value (\$100.00 per share) of the Series A Preferred Stock accretes at an annual rate of 7% compounded quarterly. On an annual basis, prior to the third anniversary of the original date of issuance, the holders may elect, pursuant to certain requirements, to receive the following 12 months of accretion in the form of a dividend of 7% per annum, payable quarterly in cash at the holder's option. After the third anniversary of the closing, such accretion may be made in cash at the Company's option. The Series A Preferred Stock is subject to certain default provisions whereby the dividend rate would be increased by an additional 5% per annum.

After the third anniversary of the original date of issuance, the Company can force conversion of all, and not less than all, of the outstanding Series A Preferred Stock into Company common stock as long as the closing price of our common stock is at least 250% of the Conversion Price, or \$7.05 per common share, for at least 20 of the 30 consecutive trading days immediately prior to the conversion and the average daily trading volume is greater than 50,000 shares per day over the 30 consecutive trading days immediately prior to such conversion. The Company's ability to cause a conversion is subject to certain other conditions as provided pursuant to the terms of the Series A Preferred Stock.

The Series A Preferred Stock is entitled to a liquidation preference equal to the greater of 100% of the accreted value for each share of Series A Preferred Stock outstanding on the date of a liquidation plus all accrued and unpaid dividends or the amount a holder would have been entitled to had the holder converted the shares of Series A Preferred Stock into common stock immediately prior to the liquidation. The Series A Preferred Stock votes together with the common stock as if converted on the original date of issuance. Holders of Series A Preferred Stock are entitled to purchase their pro rata share of additional stock issuances in certain future financings.

Series A Exchangeable Preferred Stock

Prior to approval by the stockholders of the Company at the Special Meeting of Stockholders held on August 22, 2011, holders of the Series A Exchangeable Preferred Stock did not have any voting rights, and the stated value of the Series A Exchangeable Preferred Stock of \$100.00 per share accreted at an annual rate of 10%, compounded quarterly. The Series A Preferred Stock was initially recorded as temporary equity as holders had the right to redeem their shares for cash five years from the issuance date. The redemption right terminated upon stockholder approval at which time the Company reclassified the Series A Exchangeable Preferred Stock, including accretion of \$112,509, to permanent equity. Following approval by the stockholders of the Company, the Series A Exchangeable Preferred Stock now has substantially identical terms to the Series A Preferred Stock.

Pursuant to the terms of the Series A Preferred Stock and Series A Exchangeable Preferred Stock, a holder must issue a written request to the Company by June 15th of 2011, 2012, or 2013 to receive cash dividends for the applicable succeeding four fiscal quarters ending June 30th, September 30th, December 31st, and March 31st. The holders have elected in writing not to receive cash dividends for the fiscal quarters through June 30, 2013. Further, the holders have irrevocably waived their cash dividend rights for the four fiscal quarters ending June 30, 2014, in accordance with the Company's agreement with East West Bank executed on July 31, 2012. The bank agreement prohibits the payment of cash dividends. The holders' waiver of their cash dividend rights for the four fiscal quarters ending June 30, 2014, may be revoked if the Company's obligations to East West Bank are terminated at any time prior to June 30, 2014. As of March 31, 2013, \$2,047,583 in dividend accretion has accumulated on the Series A Preferred Stock and the Series A Exchangeable Preferred Stock.

(4) Bank Financing

On July 31, 2012, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with East West Bank (the "Bank"). Pursuant to the Loan Agreement, the Bank provided the Company with a secured three-year \$3,500,000 term loan (the "Term Loan") which bears interest at 5.5% and contained a 12-month interest-only feature. On May 10, 2013, the Company amended the Loan Agreement which increased the principal to \$5,000,000 and extended the maturity date of the Term Loan to July 31, 2016, with principal payable in 24 equal installments of approximately \$221,000 including interest commencing August 1, 2014. The interest rate was modified to 5.75%.

The Loan Agreement, as amended, also contains a revolving line-of-credit (the “Revolver”) facility with maximum borrowings of \$2,000,000 and an expiration date of July 31, 2014. Under the amended Loan Agreement, advances under the Revolver bear interest at a floating rate equal to 2.00% above the Bank’s prime rate, with a 3.25% floor on the prime rate, representing an effective rate of 5.25%, as of March 31, 2013. Interest on the loan is payable monthly. The Company is permitted to borrow against eligible accounts receivable as defined under the Revolver according to pre-established criteria. The amount available for borrowing under the Revolver as of March 31, 2013, was \$1,471,000. There were no borrowings under the Revolver as of March 31, 2013.

The obligations under the Loan Agreement, as amended, are secured by a lien on substantially all assets of the Company, excluding intellectual property, provided that, following an event of default, such security interest would also include intellectual property.

The Loan Agreement, as amended, contains customary negative covenants limiting the ability of the Company and its subsidiaries, among other things, to grant liens on the pledged collateral, pay cash dividends, make certain investments and acquisitions, and dispose of assets outside the ordinary course of business. The amended agreement also contains financial covenants, measured quarterly, providing a minimum level of the Company’s tangible net worth, and non-financial covenants with respect to the timing of certain new product approvals. As of March 31, 2013, the Company was in compliance with the Loan Agreement covenants.

In connection with the Loan Agreement, on July 31, 2012, the Company issued to the Bank a warrant to purchase 133,333 shares of Company common stock for a five-year period expiring on July 31, 2017, at an exercise price of \$1.80 per share which approximated the market value of the common stock at the grant date. The warrant was valued at \$145,732 using the Black-Scholes option pricing model using the following assumptions: fair value of the underlying common stock of \$1.80, a weighted average expected stock price volatility of 75.5%, an expected warrant life of five years, an average risk-free interest rate of 0.62%, and a 0.0% average dividend yield. The warrant was fully vested at time of issuance. The warrant cost was recorded as a debt discount and is being recognized as interest expense over the three-year period of the Term Loan using the effective interest method.

In connection with the amendment dated May 10, 2013, the Company issued to the Bank a warrant to purchase 30,257 shares of common stock for a five-year period expiring on May 10, 2018, at an exercise price of \$1.98 per share which approximated the market value of the common stock at the grant date. The warrant was valued at \$31,878 using the Black-Scholes option pricing model using the following assumptions: fair value of the underlying common stock of \$1.98, a weighted-average expected stock price volatility of 63.6%, an expected warrant life of five years, an average risk-free interest rate of 0.71%, and a 0.0% average dividend yield. The warrant was fully vested at time of issuance. The warrant cost was recorded as a debt discount and is being recognized as interest expense over the three-year period of the Term Loan using the effective interest method.

The outstanding balance of the bank term loan is as follows:

	March 31, 2013	December 31, 2012
	<u> </u>	<u> </u>
Balance of bank term loan	\$ 3,500,000	\$ 3,500,000
Debt discount	(99,129)	(116,606)
	<u>3,400,871</u>	<u>3,383,394</u>
Current portion	—	697,834
Long-term portion	<u>\$ 3,400,871</u>	<u>\$ 2,685,560</u>

(5) Inventories, Property and Equipment, Intangible and Other Assets

Inventories consist of:

	<u>March 31, 2013</u>	<u>December 31, 2012</u>
Raw materials	\$ 2,870,723	\$ 2,489,750
Work in process	16,868	34,384
Finished goods	1,002,458	1,019,191
	<u>\$ 3,890,049</u>	<u>\$ 3,543,325</u>

Property and equipment are stated at cost and include FORE-SIGHT cerebral oximetry monitors primarily located at customer sites within the United States. Such equipment is typically held under a no-cost program whereby customers purchase disposable sensors for use with the Company's equipment. The Company retains title to the monitors shipped to its customers under this program. Property and equipment is depreciated using the straight-line method over the estimated useful lives of the assets.

Intangible assets consist of patents issued, patents pending, trademarks, and purchased technology which are recorded at cost. Patents are amortized on a straight-line basis over 20 years. Capitalized costs are amortized over their estimated useful lives.

Intangible and other assets consist of the following:

	<u>March 31, 2013</u>	<u>December 31, 2012</u>
Patents and other assets	\$ 756,180	\$ 714,810
Patents pending	304,507	348,256
Purchased technology	43,893	46,026
Deferred financing costs	147,931	147,931
	<u>1,252,511</u>	<u>1,257,023</u>
Accumulated amortization	(444,962)	(426,778)
	<u>\$ 807,549</u>	<u>\$ 830,245</u>

Amortization expense of intangible and other assets for the three months ended March 31, 2013, was \$27,120. Estimated amortization expense for the calendar year 2013 is \$105,300. Expected amortization expense of intangible and other assets for the next five calendar years and beyond follows:

2014	\$ 78,000
2015	47,100
2016	17,700
2017	17,700
2018	17,700
Thereafter	171,200
	<u>\$ 349,400</u>

The Company reviews its intangibles and other assets for impairment at least annually or whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company believes that the carrying amounts of its remaining long-lived assets are fully recoverable.

(6) Principal Products and Services

The Company has categorized its sales of products and services into the following categories:

- Tissue oximetry monitoring products – includes sales of the FORE-SIGHT cerebral monitors, sensors, and accessories.
- Traditional vital signs monitoring products - includes:
 - 1) Vital signs bedside monitors and accessories, incorporating various combinations of measurement parameters for both human and veterinary use. Parameters found in these monitors include the Company's proprietary MAXNIBP non-invasive blood pressure, pulse oximetry, electro-cardiography, temperature, and capnography.
 - 2) Blood pressure measurement technology – includes sales to OEM manufacturers of the Company's proprietary, MAXNIBP non-invasive blood pressure technology, sold as a discrete module to be included in the OEM customers' own multi-parameter monitors, and related license fees.
 - 3) Supplies and service – includes sales of neonatal intensive care supplies, including electrodes, skin temperature probes, and service repair.

(7) Loss per Common Share Applicable to Common Stockholders

Basic earnings per share is calculated by dividing net loss applicable to common stockholders by the weighted-average number of common shares outstanding for the period. Diluted loss per share reflects the potential dilution that could occur if common stock equivalents such as unvested restricted common shares, outstanding warrants and options, or convertible preferred stock were exercised or converted into common stock. For all periods reported, the Company incurred net losses. Therefore, for each period reported, diluted loss per share is equal to basic loss per share because the effect of including such common stock equivalents or other securities would have been anti-dilutive.

At March 31, 2013, stock options and warrants to purchase 2,007,125 and 1,022,734 shares of common stock, respectively, were excluded from the diluted earnings per share calculation as they would have been anti-dilutive. On an as-converted basis, 6,045,242 shares of common stock pertaining to the private placement of 150,000 shares of Series A convertible and exchangeable preferred stock issued on June 9, 2011, were also excluded as they would have been anti-dilutive.

The following table presents a reconciliation of the numerators and denominators of basic and diluted loss per share:

	Three Months Ended	
	March 31,	
	2013	2012
Net loss	\$ (1,587,183)	\$ (1,946,092)
Preferred stock dividend accretion	293,201	273,545
Net loss applicable to common stockholders	<u>\$ (1,880,384)</u>	<u>\$ (2,219,637)</u>
Weighted-average shares outstanding, net of unvested restricted common shares – used to compute basic and diluted loss per share applicable to common stockholders	<u>13,391,752</u>	<u>13,218,840</u>

(8) Stock Compensation Expense and Share-based Payment Plans

Stock compensation expense was \$228,419 and \$228,648 for the three-month periods ended March 31, 2013 and 2012, respectively.

As of March 31, 2013, the unrecognized stock-based compensation cost related to stock option awards and unvested restricted common stock was \$1,863,000. Such amount, net of estimated forfeitures, will be recognized in operations through the fourth quarter of 2016.

The following table summarizes the Company's stock option information as of and for the three-month period ended March 31, 2013:

	<u>Option Shares</u>	<u>Weighted- Average Exercise Price</u>	<u>Aggregate Intrinsic Value (1)</u>	<u>Weighted- Average Contractual Life Remaining in Years</u>
Outstanding at December 31, 2012	2,007,125	\$ 2.25	\$ 307,406	8.0
Granted	—	—	—	
Cancelled	—	—	—	
Exercised	—	—	—	
Outstanding at March 31, 2013	<u>2,007,125</u>	<u>\$ 2.25</u>	<u>\$ 136,500</u>	<u>7.7</u>
Exercisable at March 31, 2013	<u>815,417</u>	<u>\$ 2.36</u>	<u>\$ 64,313</u>	<u>6.2</u>
Vested and expected to vest at March 31, 2013	<u>1,971,419</u>	<u>\$ 2.25</u>	<u>\$ 134,337</u>	<u>7.7</u>

(1) The intrinsic value of a stock option is the amount by which the market value, as of the applicable date, of the underlying stock exceeds the option exercise price.

The exercise period for all outstanding stock options may not exceed ten years from the date of grant. Stock options granted to employees and members of the Board of Directors vest typically not less than three years from the grant date. The Company attributes stock-based compensation cost to operations using the straight-line method over the applicable vesting period.

On June 8, 2011, at the Company's annual meeting of stockholders, the CAS Medical Systems, Inc. 2011 Equity Incentive Plan (the "2011 Plan") was approved by its stockholders. The 2011 Plan provides for the availability of a maximum of 1,000,000 shares of the Company's common stock, with a maximum of 500,000 shares available for issuance with respect to awards of restricted stock and restricted stock units.

The purposes of the Incentive Plan are to make available to key employees and directors, certain compensatory arrangements related to growth in the value of the Company's stock so as to generate an increased incentive to contribute to the Company's financial success and prosperity, to enhance the Company's ability to attract and retain exceptionally qualified individuals whose efforts can affect the Company's financial growth and profitability, and to align, in general, the interests of employees and directors with the interests of stockholders. As of March 31, 2013, 117,000 shares of common stock remained available for issuance under the 2011 Plan. As such, the Compensation Committee of the Board of Directors has voted to include a proposal for election at the Company's 2013 annual meeting on June 20, 2013, to amend the Incentive Plan. The amendment, if approved by the Company's stockholders, would increase the amount of shares under the Incentive Plan by 1,000,000 to a total of 2,000,000 shares.

There were no stock options issued during the three months ended March 31, 2013.

During the first quarter of 2013, the Company's President and Chief Executive Officer received a grant of 11,000 shares of common stock in lieu of a cash payment for a portion of his 2012 management bonus.

There were no grants of restricted stock during the three months ended March 31, 2013. As of March 31, 2013, 290,651 restricted shares issued to employees and members of the Board of Directors remain issued and non-vested. The unamortized stock compensation expense associated with the restricted shares at March 31, 2013, was \$291,000 and will be recognized through the first quarter of 2015.

A summary of the restricted shares outstanding and changes for the relevant periods follow:

	Three Months Ended March 31, 2013		Weighted- Average Grant Date Fair-Value
	<u> </u>		<u> </u>
Outstanding at beginning of period	320,476	\$	2.19
Granted	—		—
Cancelled	—		—
Vested	(29,825)		2.18
Outstanding at end of period	<u>290,651</u>	<u>\$</u>	<u>2.19</u>

(9) Short-term Investments

The Company's short-term investments are held in certificates of deposit ("CDs") with maturities greater than three months. These investments are recorded at amortized cost.

(10) Income Taxes

The Company does not expect to record taxable income during its 2013 fiscal year. As such, income tax benefits that may be generated during 2013 would be offset by a deferred income tax asset valuation allowance. Management established the valuation allowance at December 31, 2009, as a result of cumulative pre-tax losses and its estimates of future taxable income. Management has continued to perform the required analysis regarding the realization of our deferred income tax assets concluding that a full valuation allowance is warranted. As of March 31, 2013, the deferred income tax asset valuation allowance balance was \$6,608,000.

(11) Legal Proceedings

On December 29, 2011, Nellcor Puritan Bennett, LLC, ("Nellcor") filed an action against the Company in the United States District Court for the Eastern District of Michigan alleging (i) breach of the settlement agreement with respect to a prior litigation matter between the parties, (ii) violation of the Lanham Act, (iii) common law unfair competition, and (iv) trade libel. The complaint requested injunctive relief and unspecified monetary damages, including compensatory damages and reasonable attorneys' fees. On February 24, 2012, the Company answered the complaint and denied substantially all of the claims and set forth certain affirmative defenses. On July 20, 2012, Nellcor filed a partial motion for summary judgment asking the Court to determine that the Company breached the settlement agreement. On December 19, 2012, the Court denied Nellcor's motion for summary judgment, finding that the Company did not breach the settlement agreement. Discovery has now closed, and additional motions for summary judgment and other matters have been filed by both parties. The matter remains pending, and while there can be no assurance as to the ultimate outcome, the Company does not believe at this time that its disposition would result in a material adverse effect on the Company.

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Certain statements included in this report, including without limitation statements in Management's Discussion and Analysis of Financial Condition and Results of Operations, which are not historical facts, are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements represent the Company's current expectations regarding future events. The Company cautions that such statements are qualified by important factors that could cause actual results to differ materially from expected results which may be contained in the forward-looking statements. All forward-looking statements involve risks and uncertainties, including, but not limited to, the following: foreign currency fluctuations, regulations and other economic and political factors which affect the Company's ability to market its products internationally, changes in economic conditions that adversely affect demand for the Company's products, potential liquidity constraints, new product introductions by the Company's competitors, increased price competition, rapid technological changes, dependence upon significant customers, availability and cost of components for the Company's products, the impact of any product liability or other adverse litigation, marketplace acceptance for the Company's new products, FDA and other governmental regulatory and enforcement actions, changes in reimbursement levels from third-party payors, changes to federal research and development grant programs presently utilized by the Company and other factors described in greater detail in the Company's most recent annual report on Form 10-K.

Results of Operations

For the three months ended March 31, 2013, the Company reported a net loss applicable to common stockholders of \$1,880,000, or (\$0.14) per basic and diluted common share, compared to a net loss applicable to common stockholders of \$2,220,000, or (\$0.17) per basic and diluted common share, for the three months ended March 31, 2012.

The Company generated revenues of \$5,576,000 for the three months ended March 31, 2013, an increase of \$167,000, or 3%, compared to revenues of \$5,409,000 for the three months ended March 31, 2012. The following table provides information with respect to revenues by major category:

Total Revenues (\$000's)

	<u>Three Months Ended March 31, 2013</u>	<u>Three Months Ended March 31, 2012</u>	<u>Increase/ (Decrease)</u>	<u>% Change</u>
Tissue Oximetry Monitoring	\$ 2,234	\$ 1,704	\$ 530	31%
Traditional Vital Signs Monitoring	3,342	3,705	(363)	(10%)
	<u>\$ 5,576</u>	<u>\$ 5,409</u>	<u>\$ 167</u>	<u>3%</u>
Domestic Sales	\$ 4,225	\$ 4,211	\$ 14	0%
International Sales	1,351	1,198	153	13%
	<u>\$ 5,576</u>	<u>\$ 5,409</u>	<u>\$ 167</u>	<u>3%</u>

Tissue oximetry product revenues of \$2,234,000 for the three months ended March 31, 2013, were \$530,000, or 31%, above the \$1,704,000 reported for the same period in the prior year led by increased sensor sales. As of March 31, 2013, the Company's worldwide installed base of oximetry monitors was 773 units, an increase of 31% above the installed base of 592 as of March 31, 2012.

Traditional vital signs monitoring product revenues for the three months ended March 31, 2013, decreased \$363,000, or 10%, to \$3,342,000 from \$3,705,000 reported for the same period in the prior year. Decreases in international sales of vital signs monitors, often influenced by large tenders, were responsible for the reduction and were partially offset by increases in vital signs monitor sales to U.S. customers.

Sales of all products to the U.S. market accounted for \$4,225,000, or 76%, of the total revenues reported for the three months ended March 31, 2013, an increase of \$14,000 from the \$4,211,000 of U.S. sales reported for the three months ended March 31, 2012. International sales of all products accounted for \$1,351,000, or 24%, of the total revenues reported for the three months ended March 31, 2013, an increase of \$153,000, or 13%, from the \$1,198,000 reported for the same period of the prior year.

The following table provides information with respect to tissue oximetry revenues:

Tissue Oximetry Revenues (\$000's)

	Three Months Ended March 31, 2013	Three Months Ended March 31, 2012	Increase/ (Decrease)	% Change
Sensor Sales	\$ 1,858	\$ 1,445	\$ 413	29%
Monitors & Accessories	376	259	117	45%
	<u>\$ 2,234</u>	<u>\$ 1,704</u>	<u>\$ 530</u>	<u>31%</u>
Domestic Sales	\$ 1,793	\$ 1,330	\$ 463	35%
International Sales	441	374	67	18%
	<u>\$ 2,234</u>	<u>\$ 1,704</u>	<u>\$ 530</u>	<u>31%</u>

Worldwide sales of tissue oximetry products increased 31% for the first quarter of 2013 led by sales of disposable sensors. Worldwide sensor sales increased 29%, to \$1,858,000 for the first quarter of 2013 from \$1,445,000 for the first quarter of 2012. Domestic tissue oximetry product sales were \$1,793,000, an increase of \$463,000, or 35%, from the \$1,330,000 recorded for the first quarter of 2012 as a result of both improved monitor and sensor sales. International tissue oximetry product sales were \$441,000, an increase of \$67,000, or 18%, from the first quarter of 2012 as a result of increased sensor sales.

Gross profit was \$2,225,000 or 40% of sales for the three months ended March 31, 2013, compared to \$2,035,000, or 38% of sales for the same period of the prior year. The improvement resulted primarily from manufacturing productivity gains.

Total operating expenses for the three months ended March 31, 2013, increased \$137,000, or 3%, to \$4,135,000 from \$3,998,000 for the three months ended March 31, 2012.

Research and development expenses increased \$163,000, or 18%, to \$1,053,000 for the three months ended March 31, 2013, compared to \$890,000 for the three months ended March 31, 2012. R&D expenses for the three months ended March 31, 2012, were net of \$130,000 of reimbursements from the National Institutes of Health ("NIH"). The Company's NIH grant expired in late 2012, and no further reimbursements are available. Increased engineering project expenditures accounted for the balance of the increased R&D spending.

Selling, general, and administrative ("S,G&A") expenses decreased \$26,000, or 1%, to \$3,082,000 for the three months ended March 31, 2013, compared to \$3,108,000 for the three months ended March 31, 2012. The decrease in S,G&A for the three months ended March 31, 2013, was primarily related to lower costs for trade shows and international selling expenses, largely offset by the recently enacted medical device excise tax and increased legal expenses.

Management expects operating expenses to increase for the duration of the 2013 calendar year over first quarter 2013 spending levels primarily due to increases in R&D and selling expenses.

Interest expense of \$66,000 for the three months ended March 31, 2013, primarily reflects the Company's term debt agreement with its bank lender executed July 31, 2012.

Other income was \$388,000 for the three months ended March 31, 2013, compared to \$17,000 of income for the three months ended March 31, 2012. During January 2013, the Company received \$381,000 related to the sale and demutualization of one of its commercial insurance providers.

The Company does not expect to record taxable income during its 2013 fiscal year. Income tax benefits that may be generated during 2013 would be offset by a deferred income tax asset valuation allowance.

Management established the valuation allowance as of December 31, 2009, as a result of cumulative pre-tax losses and its estimates of future taxable income. Management has continued to perform the required analysis regarding the realization of our deferred income tax assets concluding that a full valuation allowance is warranted. As of March 31, 2013, the deferred income tax asset valuation allowance balance was \$6,608,000.

Financial Condition, Liquidity and Capital Resources

As of March 31, 2013, the Company's cash and cash equivalents and short-term investments totaled \$7,746,000 compared to \$10,496,000 as of December 31, 2012. Working capital decreased \$577,000 to \$12,042,000 as of March 31, 2013, from \$12,619,000 as of December 31, 2012.

Cash used in operations for the three months ended March 31, 2013, was \$2,946,000 compared to cash used in operations of \$1,798,000 for the same period in the prior year. The increase in cash used from operations over the prior year period primarily related to increase in inventory and decreases in accounts payable and accrued expenses.

Cash provided by investing activities was \$656,000 for the three months ended March 31, 2013, compared to cash used in investing activities of \$415,000 for the same period in the prior year. Short-term investments of \$493,000 for the three-months ended March 31, 2013, pertains to the transfer of funds from fully-matured certificates of deposit classified as short-term investments to the Company's principal operating account. Expenditures for property and equipment of \$213,000 for the three-months ended March 31, 2013, were primarily comprised of manufacturing equipment and FORE-SIGHT cerebral oximeter customer placements. Cash flows from investing activities for the three months ended March 31, 2013, include \$381,000 of income from the sale and demutualization of the Company's insurance provider during January 2013.

On July 31, 2012, the Company entered into a Loan and Security Agreement (the "Loan Agreement") with East West Bank (the "Bank"). Pursuant to the Loan Agreement, the Bank provided the Company with a secured three-year \$3,500,000 term loan (the "Term Loan") which bears interest at 5.5% and contained a 12-month interest-only feature. On May 10, 2013, the Company amended the Loan Agreement which increased the principal to \$5,000,000 and extended the maturity date of the Term Loan to July 31, 2016, with principal payable in 24 equal installments of approximately \$221,000 including interest commencing August 1, 2014. The interest rate was modified to 5.75%.

The Loan Agreement, as amended, also contains a revolving line-of-credit (the "Revolver") facility with maximum borrowings of \$2,000,000 and an expiration date of July 31, 2014. Under the amended Loan Agreement, advances under the Revolver bear interest at a floating rate equal to 2.00% above the Bank's prime rate, with a 3.25% floor on the prime rate, representing an effective rate of 5.25%, as of March 31, 2013. Interest on the loan is payable monthly. The Company is permitted to borrow against eligible accounts receivable as defined under the Revolver according to pre-established criteria. The amount available for borrowing under the Revolver as of March 31, 2013, was \$1,471,000. There were no borrowings under the Revolver as of March 31, 2013.

Our 2013 business plans call for increased operating expenditures primarily to develop and market our FORE-SIGHT® technology and our other product lines. Our ordinary short-term capital needs are expected to be met from our current cash on hand and amounts available under our Loan Agreement with East West Bank. However, we may, from time to time, seek additional funding through a combination of equity and debt financings or from other sources.

Critical Accounting Policies and Estimates

The Company's discussion and analysis of financial condition and results of operations are based on the condensed consolidated financial statements. The preparation of these financial statements requires the Company to make estimates and judgments that affect the amounts reported in them. The Company's critical accounting policies and estimates include those related to revenue recognition, the valuations of inventories and deferred income tax assets, measuring stock compensation and warranty costs, determining useful lives of intangible assets, and making asset impairment valuations. The Company bases its estimates on historical experience and on various other assumptions that management believes to be reasonable under the circumstances. Actual results may differ from these estimates under different assumptions or conditions. For additional information about the Company's critical accounting policies and estimates, see Item 7 and Note 2 to the financial statements included in the Company's Form 10-K for the year ended December 31, 2012. There were no significant changes in critical accounting policies and estimates during the three months ended March 31, 2013.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

The Company at times has certain exposures to market risk related to changes in interest rates. The Company holds no derivative securities for trading or other purposes and is not subject in any material respect to currency or other commodity risk.

ITEM 4. CONTROLS AND PROCEDURES

The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed in the Company's Exchange Act reports is recorded, processed, summarized, and reported within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure based on the definition of "disclosure controls and procedures" in Rule 13a-15(e). In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

The Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the Company's Chief Executive Officer and the Company's Chief Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures as of March 31, 2013. Based upon the foregoing evaluation, the Chief Executive Officer and Chief Financial Officer concluded that the Company's disclosure controls and procedures were effective as of that date.

There have been no changes in the Company's internal control over financial reporting during the quarter ended March 31, 2013, that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Reference is made to the Certifications of the Chief Executive Officer and the Chief Financial Officer about these and other matters attached as Exhibits 31.1, 31.2, and 32.1 to this quarterly report on Form 10-Q.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

On December 29, 2011, Nellcor Puritan Bennett, LLC, (“Nellcor”) filed an action against the Company in the United States District Court for the Eastern District of Michigan alleging (i) breach of the settlement agreement with respect to a prior litigation matter between the parties, (ii) violation of the Lanham Act, (iii) common law unfair competition, and (iv) trade libel. The complaint requested injunctive relief and unspecified monetary damages, including compensatory damages and reasonable attorneys’ fees. On February 24, 2012, the Company answered the complaint and denied substantially all of the claims and set forth certain affirmative defenses. On July 20, 2012, Nellcor filed a partial motion for summary judgment asking the Court to determine that the Company breached the settlement agreement. On December 19, 2012, the Court denied Nellcor’s motion for summary judgment, finding that the Company did not breach the settlement agreement. Discovery has now closed, and additional motions for summary judgment and other matters have been filed by both parties. The matter remains pending, and while there can be no assurance as to the ultimate outcome, the Company does not believe at this time that its disposition would result in a material adverse effect on the Company.

ITEM 6. EXHIBITS

- 31.1 Certification pursuant to Rule 13a-14(a) of Thomas M. Patton, President and Chief Executive Officer
- 31.2 Certification pursuant to Rule 13a-14(a) of Jeffery A. Baird, Chief Financial Officer
- 32.1 Certification pursuant to 18 U.S.C. 1350 of Periodic Financial Report of Thomas M. Patton, President and Chief Executive Officer and Jeffery A. Baird, Chief Financial Officer
- 101 Interactive data files pursuant to Rule 405 of Regulation S-T

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

CAS MEDICAL SYSTEMS, INC.

(Registrant)

/s/ Thomas M. Patton

Date: May 14, 2013

By: Thomas M. Patton
President and Chief Executive Officer

/s/ Jeffery A. Baird

Date: May 14, 2013

By: Jeffery A. Baird
Chief Financial Officer

CERTIFICATION

I, Thomas M. Patton, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CAS Medical Systems, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Thomas M. Patton
Thomas M. Patton
President and Chief Executive Officer

Date: May 14, 2013

CERTIFICATION

I, Jeffery A. Baird, certify that:

1. I have reviewed this quarterly report on Form 10-Q of CAS Medical Systems, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c. Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d. Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

/s/ Jeffery A. Baird
Jeffery A. Baird
Chief Financial Officer

Date: May 14, 2013

Certification of Periodic Financial Report

Pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, Thomas M. Patton, the President and Chief Executive Officer, and Jeffery A. Baird, the Chief Financial Officer of CAS Medical Systems, Inc. (the "issuer"), do hereby certify that the quarterly report on Form 10-Q accompanying this certification (the "report") fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)) and that information contained in the report fairly presents, in all material respects, the financial condition and results of operations of the issuer.

/s/ Thomas M. Patton
Thomas M. Patton
President and Chief Executive Officer
CAS Medical Systems, Inc.

Date: May 14, 2013

/s/ Jeffery A. Baird
Jeffery A. Baird
Chief Financial Officer
CAS Medical Systems, Inc.

Date: May 14, 2013

casm-20130331.xml is Missing in the Submission Header

casm-20130331.xsd is Missing in the Submission Header

casm-20130331_cal.xml is Missing in the Submission Header

casm-20130331_def.xml is Missing in the Submission Header

casm-20130331_lab.xml is Missing in the Submission Header

casm-20130331_pre.xml is Missing in the Submission Header
